BioSpace News Archive

With manufacturers focusing on expansion of their product lines, sterile active pharmaceutical ingredients market will exhibit growth at accelerated pace

Transparency Market Research has published a new report titled, ‘Bioprocess Technology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

BIOPHYTIS SA announces the approval by a very large majority of all resolutions falling within the remit of the Combined General Meeting.

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET.

Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions

Axcella Announces Initiation of EMMPACT SM Phase 2b Clinical Trial of AXA1125 Initial clinical sites activated and patient screening underway Potential for AXA1125 to serve as a first-line therapy for patients with nonalcoholic steatohepatitis (NASH)

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds.

Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, announced the appointments of Thorsten Graef, M.D., Ph.D., as chief medical officer and Michael Brock as chief strategy officer.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, provided a corporate update and reported financial results for the first quarter ended March 31, 2021.

Dr. Arnot joins an elite board assembled to aid the advancement of innovative technologies being developed to address brain injury and other life saving medical conditions